WHO expert panel recommends Oxford University-Serum Institute's anti-malaria vaccine

The R21/Matrix-M™ malaria vaccine is an easily deployable vaccine that can be manufactured at mass scale and modest cost, enabling as many as hundreds of millions of doses to be supplied to countries which are suffering a significant malaria burden.
Source: The Economic Times - Category: Consumer Health News Source Type: news